Details of Disease

General Information of Disease (ID: DISKYOM6)

Disease Name Hypersomnia
Synonyms hypersomnia; hypersomnia (disease)
Disease Class 7A21: Idiopathic hypersomnia
Definition A sleep disorder characterized by excessive sleepiness.
Disease Hierarchy
DISOBM0Q: Sleep-wake disorder
DISKYOM6: Hypersomnia
ICD Code
ICD-11
ICD-11: 7A21
ICD-10
ICD-10: G47.1
Expand ICD-11
'7A21; '7A24
Expand ICD-10
'G47.1
Disease Identifiers
MONDO ID
MONDO_0005466
MESH ID
D006970
UMLS CUI
C0917799
MedGen ID
214588
HPO ID
HP:0100786
SNOMED CT ID
77692006

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
TS-091 DMTSC02 Phase 2 NA [1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 11 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
CPT1B TTDL0NY moderate Biomarker [2]
AMOT TTI48OS Strong Biomarker [3]
GNAQ TTL1SRG Strong Biomarker [4]
HRH3 TT9JNIC Strong Biomarker [5]
LIFR TTID542 Strong Biomarker [4]
MCHR1 TTX4RTB Strong Biomarker [6]
MTNR1B TT32JK8 Strong Biomarker [7]
PNPLA6 TTWAQU2 Strong Biomarker [4]
SCN11A TTN9VTF Strong Altered Expression [8]
SCN2A TTLJTUF Strong Genetic Variation [9]
SIK3 TTW6L4V Strong Genetic Variation [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DTT(s)
This Disease Is Related to 1 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
CHKB DEHWR6V moderate Biomarker [2]
------------------------------------------------------------------------------------
This Disease Is Related to 4 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
NCKAP5 OT5JOYZS Strong Genetic Variation [11]
PSG5 OTHTU98X Strong Biomarker [12]
PTPA OTRGFOI7 Strong Genetic Variation [13]
REM1 OTUXL0HC Strong Biomarker [14]
------------------------------------------------------------------------------------

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038071)
2 Polymorphism located between CPT1B and CHKB, and HLA-DRB1*1501-DQB1*0602 haplotype confer susceptibility to CNS hypersomnias (essential hypersomnia).PLoS One. 2009;4(4):e5394. doi: 10.1371/journal.pone.0005394. Epub 2009 Apr 30.
3 Genome-wide gene expression array identifies novel genes related to disease severity and excessive daytime sleepiness in patients with obstructive sleep apnea.PLoS One. 2017 May 17;12(5):e0176575. doi: 10.1371/journal.pone.0176575. eCollection 2017.
4 Daytime Central Thalamic Deep Brain Stimulation Modulates Sleep Dynamics in the Severely Injured Brain: Mechanistic Insights and a Novel Framework for Alpha-Delta Sleep Generation.Front Neurol. 2019 Feb 4;10:20. doi: 10.3389/fneur.2019.00020. eCollection 2019.
5 The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders.ChemMedChem. 2019 Jul 3;14(13):1238-1247. doi: 10.1002/cmdc.201900176. Epub 2019 May 21.
6 Dynamic REM Sleep Modulation by Ambient Temperature and the Critical Role of the Melanin-Concentrating Hormone System.Curr Biol. 2019 Jun 17;29(12):1976-1987.e4. doi: 10.1016/j.cub.2019.05.009. Epub 2019 May 30.
7 Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients.J Mol Neurosci. 2011 Oct;45(2):304-8. doi: 10.1007/s12031-011-9522-6. Epub 2011 Apr 28.
8 A new piperazine derivative: 1-(4-(3,5-di-tert-butyl-4-hydroxybenzyl) piperazin-1-yl)-2-methoxyethan-1-one with antioxidant and central activity.Naunyn Schmiedebergs Arch Pharmacol. 2018 Mar;391(3):255-269. doi: 10.1007/s00210-017-1451-7. Epub 2017 Dec 19.
9 Infantile epileptic encephalopathy, transient choreoathetotic movements, and hypersomnia due to a De Novo missense mutation in the SCN2A gene.Neuropediatrics. 2014 Aug;45(4):261-4. doi: 10.1055/s-0034-1372302. Epub 2014 Apr 7.
10 A single phosphorylation site of SIK3 regulates daily sleep amounts and sleep need in mice.Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):10458-10463. doi: 10.1073/pnas.1810823115. Epub 2018 Sep 25.
11 Genome-wide association study of HLA-DQB1*06:02 negative essential hypersomnia.PeerJ. 2013 Apr 16;1:e66. doi: 10.7717/peerj.66. Print 2013.
12 Prevalence, risk factors, and response to treatment for hypersomnia of central origin in survivors of childhood brain tumors.J Neurooncol. 2018 Jan;136(2):379-384. doi: 10.1007/s11060-017-2662-y. Epub 2017 Nov 8.
13 A variant at 9q34.11 is associated with HLA-DQB1*06:02negative essential hypersomnia.J Hum Genet. 2018 Dec;63(12):1259-1267. doi: 10.1038/s10038-018-0518-8. Epub 2018 Sep 28.
14 Secondary hypersomnia as an initial manifestation of neuromyelitis optica spectrum disorders.Mult Scler Relat Disord. 2020 Feb;38:101869. doi: 10.1016/j.msard.2019.101869. Epub 2019 Nov 25.